Clinical Trials

126 enrolled

Burkitt Lymphoma, Lymphoma, Lymphoma, Non-Hodgkin, Philadelphia Chromosome, Leukemia, B-Cell, Lymphoma, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06395103 2026-03-11

MK-9999-01A

90 enrolled

CNSLymphoidSarcoma

Burkitt Lymphoma, Neuroblastoma, Sarcoma, Ewing, Lymphoma, Large B-Cell, Diffuse

NCT06343090 2026-03-10

Clinical Trial of CD19 and CD22 CAR Sequential Therapy Versus Single CD19 CAR Bridging to HSCT for r/r B-ALL Patients

353 enrolled

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06326008 2026-03-09

Safety, Tolerability, and Pharmacokinetics of Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-derived CD22 CAR Therapy for r/r B-ALL: a Clinical Trial

48 enrolled

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05157971 2026-03-05

Venetoclax and a Pediatric-Inspired Regimen for the Treatment of Newly Diagnosed B Cell Acute Lymphoblastic Leukemia

24 enrolled

Burkitt Lymphoma

NCT07109219 2026-03-04

ALLight

83 enrolled

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06173518 2026-03-02

A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)

30 enrolled

Burkitt Lymphoma, Recurrence, Lymphoma, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07078929 2026-03-02

CMD63

16 enrolled

Burkitt Lymphoma

NCT04195633 2026-02-27

Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies

60 enrolled

Burkitt Lymphoma, Hodgkin Disease, Lymphoma, Follicular, Myelodysplastic Syndromes, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Biphenotypic, Acute, Leukemia, Prolymphocytic, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06389305 2026-02-25

CIK Cell Therapy for Relapsed or Refractory Acute B-Lymphoblastic Leukemia: Prognostic Impact on Patients With Early CAR-T Cell Dysfunction

213 enrolled

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04739813 2026-02-24

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma

55 enrolled

Phase EARLY_PHASE1 Recruiting

Burkitt Lymphoma, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT07429461 2026-02-24

Clinical Study of SYNCAR-100 in the Treatment of Relapsed/Refractory Acute B-Lymphoblastic Leukemia

16 enrolled

Burkitt Lymphoma, Leukemia

NCT02981628 2026-02-23

Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia

80 enrolled 1 FDA

Burkitt Lymphoma, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

NCT07153796 2026-02-23

A Phase 2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Combination With Low Intensity Chemotherapy in Older Patients With Newly Diagnosed B-cell Acute Lymphoblastic Leukemia

60 enrolled

Burkitt Lymphoma

NCT03810196 2026-02-20

CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post TCRαβ/CD19 Depleted HSCT

50 enrolled

Burkitt Lymphoma, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Myelomonocytic, Juvenile

NCT05389423 2026-02-19

Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas

25 enrolled

Plasmablastic Lymphoma, Burkitt Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Epstein-Barr Virus Infections

NCT06863259 2026-02-18

Study of Inotuzumab Ozogamicin, Venetoclax, and Dexamethasone for Relapsed B-cell ALL

28 enrolled

Burkitt Lymphoma, Recurrence

NCT03136146 2026-02-17

Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia

42 enrolled

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04094311 2026-02-17

Study of Out of Specification for Tisagenlecleucel

Phase 3 Recruiting

200 enrolled

Burkitt Lymphoma, Recurrence, Lymphoma, Large B-Cell, Diffuse, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07223021 2026-02-17

A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia

Phase 3 Recruiting

130 enrolled

Burkitt Lymphoma

NCT05544019 2026-02-13

Study of SGR-1505 in Mature B-Cell Neoplasms

98 enrolled

Plasmablastic Lymphoma, Burkitt Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Pyloric Stenosis, Hypertrophic, Lymphoma, Primary Effusion

NCT06533579 2026-02-12

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

32 enrolled

Burkitt Lymphoma, Leukemia, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Biphenotypic, Acute, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT06710418 2026-02-12

Evaluating the Effects of Hemoglobin Threshold-specific Packed Red Blood Cell Transfusions on Quality of Life and Functional Outcomes in Patients With High-grade Myeloid Neoplasms, Acute Myeloid Leukemia, or B Acute Lymphoblastic Lymphoma/Leukemia

50 enrolled

Burkitt Lymphoma, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Myeloid, Acute

NCT04872790 2026-02-10

Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia

20 enrolled

Burkitt Lymphoma, Leukemia, Biphenotypic, Acute

NCT06144606 2026-02-09

Study of KTE-X19 in Minimal Residual Disease (MRD) Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL)

60 enrolled

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06580301 2026-02-06

Study of YK012 in B-cell Acute Lymphoblastic Leukemia

46 enrolled

Burkitt Lymphoma

NCT07134088 2026-01-29

A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia

104 enrolled

Burkitt Lymphoma, Recurrence, Neoplasm, Residual

NCT05674175 2026-01-23

Co-administration of CART22-65s and huCART19 for B-ALL

93 enrolled

Burkitt Lymphoma

NCT06137118 2026-01-16

SYRUS

163 enrolled

Burkitt Lymphoma, Leukemia

NCT07097363 2026-01-15

Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma

18 enrolled

Burkitt Lymphoma, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT04545762 2026-01-14

Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma

36 enrolled

Phase EARLY_PHASE1 Recruiting

Burkitt Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT06514768 2026-01-06

JY231 (JY231) Injection for the Treatment of B-cell Acute Lymphoblastic Leukemia (B-ALL)

20 enrolled

Burkitt Lymphoma

NCT05480449 2025-12-26

Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy)

89 enrolled

Phase EARLY_PHASE1 Recruiting

Burkitt Lymphoma

NCT07205315 2025-12-26

A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic Anemia

28 enrolled

Classical hematologyLymphoidOther hematologic neoplasm

Anemia, Hemolytic, Autoimmune, Burkitt Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell

NCT06208735 2025-12-15

CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies

24 enrolled

Burkitt Lymphoma, Lymphoma, Non-Hodgkin, Leukemia, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT06080191 2025-12-02

Allogeneic Second-generation CD19-CAR T Cells for Pediatric Relapsed/Refractory B-ALL

24 enrolled

Burkitt Lymphoma

NCT06559189 2025-11-28

CD19x22 Chimeric Antigen Receptor T-cell Therapy (CAR T) in Pediatric B-ALL

53 enrolled

Burkitt Lymphoma, Hematologic Diseases, Recurrence

NCT02877303 2025-11-06

Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia

80 enrolled

Burkitt Lymphoma, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

NCT04260022 2025-11-05

Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL

242 enrolled

Blast Crisis, Burkitt Lymphoma, Leukemia, Myeloid, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03595917 2025-11-04

ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML

40 enrolled

Burkitt Lymphoma, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT03779854 2025-10-15

Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant

68 enrolled